Analyzing Natus Medical (BABY) and The Competition
Natus Medical (NASDAQ: BABY) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its peers? We will compare Natus Medical to similar companies based on the strength of its valuation, earnings, risk, dividends, analyst recommendations, institutional ownership and profitability.
Institutional & Insider Ownership
94.6% of Natus Medical shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 5.5% of Natus Medical shares are owned by insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of recent ratings and target prices for Natus Medical and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Natus Medical Competitors||258||1823||3277||105||2.59|
Natus Medical currently has a consensus price target of $48.00, indicating a potential upside of 19.40%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 8.30%. Given Natus Medical’s higher possible upside, equities analysts plainly believe Natus Medical is more favorable than its peers.
This table compares Natus Medical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Natus Medical Competitors||-370.72%||-34.80%||-11.97%|
Earnings and Valuation
This table compares Natus Medical and its peers revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Natus Medical||$445.49 million||$48.00 million||70.53|
|Natus Medical Competitors||$2.02 billion||$430.73 million||-67.50|
Natus Medical’s peers have higher revenue and earnings than Natus Medical. Natus Medical is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Natus Medical has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Natus Medical’s peers have a beta of 0.89, meaning that their average share price is 11% less volatile than the S&P 500.
Natus Medical beats its peers on 7 of the 13 factors compared.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company is organized into three strategic business units: Neurology, Newborn Care and Otometrics.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.